Seres Therapeutics, Inc. (NASDAQ:MCRB) Receives $73.67 Consensus PT from Analysts
Seres Therapeutics, Inc. (NASDAQ:MCRB – Get Free Report) has been given a consensus rating of “Reduce” by the five ratings firms that are covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and one has issued a buy recommendation on the company. […]
Seres Therapeutics, Inc. (NASDAQ:MCRB – Get Free Report) has been given a consensus rating of “Reduce” by the five ratings firms that are covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and one has issued a buy recommendation on the company. […]
